Citigroup Maintains Buy on Surgery Partners, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Jason Cassorla maintains a Buy rating on Surgery Partners (NASDAQ:SGRY) but lowers the price target from $38 to $36.
August 07, 2024 | 7:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup analyst Jason Cassorla maintains a Buy rating on Surgery Partners but lowers the price target from $38 to $36.
The Buy rating suggests continued confidence in the stock, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100